Work

Ultra‐Hypofractionated Radiotherapy for Early‐Stage Glottic Cancer: Real‐World Data From a Single Center

Year: 2025

Type: article

Abstract: ABSTRACT Background In recent years, smaller‐volume radiotherapy has attracted attention. It appears to be a safe and effective treatment for glottic laryngeal cancer. This study evaluated the results of ultra‐hypofractionated radiotherapy for early glottic laryngeal cancer in unfit patients. Methods This retrospective study analyzed 22 patients diagnosed with early glottic cancer between June 2017 and January 2021. The involved vocal cord was treated with 35–42.5 Gy in 5 fractions. Results On a 59‐month median follow‐up, the 5‐year overall survival and local control rate were 68.2% and 94.7%, respectively. However, the 5‐year larynx preservation rate was 89.7%. Chondronecrosis was observed in one patient (4.5%), and soft tissue necrosis in one patient (4.5%). PTV D98 (> 41.08 Gy) was found to be statistically significant in surgery‐needed events (HR: 22.4, 95% CI: 1.9–252.1, p = 0.01). Conclusion Single‐cord ultra‐hypofractionated radiotherapy appears to be an effective treatment for local control. However, the risk of radionecrosis is higher at doses above 41.08 Gy.

Source: Head & Neck

DOI: 10.1002/hed.28139

Authors: Mete Gundog, Esin Kiraz

Institution: Erciyes University

Language: English

Topic: Head and Neck Cancer Studies

Subfield: Otorhinolaryngology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: hybrid

Estimated APC paid: $4,760